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ABSTRACT 
 
Atherosclerotic-related cardiovascular disease (ASCVD) claims the lives of over 
600,000 Americans yearly. Current methodologies of assessment do not distinguish 
lipoprotein density distributions and instead measure lipoprotein cholesterol, with low-
density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-
C) of primary clinical relevance.  
Furthermore, the distinction between the effects of diet and exercise interventions 
on lipoproteins is frequently indiscernible due to the effects of energy deficit induced by 
interventions. High-performance lipoprotein density profiling (HPLDP) provides a cost-
effective way to rapidly assess the efficacy of diet or exercise interventions.  The 
purpose of this study is to characterize density distribution of HDL subclasses in 
response to diet or exercise using HPLDP.  
Eighty-eight untrained subjects (74% male, average age of 54 years) were pooled 
from two lifestyle intervention studies that met the inclusion criteria. Following 12 
weeks of diet or exercise interventions (750 kcal expenditure or 750 kcal deficit), 
subjects lost an average of 3.72 kg weight (-3.9%), lost 3.9 kg of body fat (-11.6%), 
increased lean mass 0.62 kg (+1.1%), and reduced body fat percentage by 3.41%            
(-9.1%). Average absolute VO2 max increased 0.16 liters O2/min (+7.1%) (p<0.05). 
Several lipoprotein density distributions were significantly different (p<0.05) between 
diet and exercise interventions (expressed as percent change from baseline): triglyceride-
rich lipoproteins (TRL) (-17.14 vs 19.65), low-density lipoprotein subfraction 5 (LDL5) 
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(-26.06 vs 8.14), high-density lipoprotein subfraction 3b (HDL3b) (-21.24 vs -0.71), and 
high-density lipoprotein subfraction 3c (HDL3c) (-17.88 vs 7.94).  To elucidate the 
effects of cardiorespiratory fitness, subjects were further divided into categories of 
increased absolute VO2 max and decreased absolute VO2 max, with no changes between 
groups at baseline. Associations between absolute VO2 max percent change on TRL, 
LDL-5, HDL-3b, and HDL-3c percent change remained significant after controlling for 
age, gender, and fat mass percent change. A regression equation was constructed from 
significant correlations and effectively predicted HDL-3c changes using absolute VO2 
max measurements. 
A significant linear relationship between improved absolute VO2 max and 
increased HDL-3c subfraction AUC exists; lipoprotein subfraction quantification may 
reveal positive effects of exercise overlooked using traditional clinical cholesterol 
assessment techniques.  
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
Approximately 610,000 Americans die annually from cardiovascular disease 
(CVD), which is responsible for one in every four deaths and the leading cause of death 
in the United States (168). Over half of those deaths are due to atherosclerotic 
cardiovascular disease (ASCVD). An insidious, multi-factorial disease process, ASCVD 
has a strong positive correlation with serum cholesterol levels (176). First described by 
Nikolai Anitschkow in 1913 and further elucidated by the Multiple Risk Factor 
Intervention Trial (MRFIT) in the 1970s, the “cholesterol hypothesis” describes the 
exponential increase in ASCVD-related mortality correlated to linear increases in serum 
cholesterol ASCVD (151, 200, 201). Advancements in cholesterol assessment methods 
has allowed for the characterization of distinct lipoprotein classes, originally named for 
their floatation densities within an ultracentrifuge field (5, 152). As such, 
epidemiological studies on lipoproteins separated by ultracentrifugation found that low-
density lipoprotein cholesterol (LDL-C) was positively correlated with the incidence of 
ASCVD, while high-density lipoprotein cholesterol (HDL-C) was negatively correlated 
with ASCVD (28, 45, 166, 193).  
In a coordinated effort to reduce the prevalence of ASCVD, public health entities 
such as the National Heart, Lung, and Blood Institute (NHLBI) and the American Heart 
Association (AHA) developed nutrition intervention policies with guidance to reduce  
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dietary fat and cholesterol intake, while increasing physical activity (30, 134, 156, 157).  
Americans have generally adhered to these recommendations, resulting in a 10% 
reduction in LDL-C and an increase of 4% in HDL-C since 1988 (28, 150).  
Complicating clinical guidelines are the variable responses observed with exercise on 
key ASCVD biomarkers, including lipoprotein and cholesterol measurements (123). 
Interestingly, 50% of people who die from ASCVD have LDL-C levels at or 
below therapeutic target concentrations, indicating the presence of residual ASCVD risk  
due to non LDL-C factors (187). Pharmacological interventions that increase HDL-C, 
such as cholesterol:ester transfer protein (CETP) antagonists, are able to increase HDL-
C up to 80%, but to date have off-target effects and do not reduce CVD risk (11, 147, 
187). This unexpected outcome underscores a lack of understanding regarding HDL 
biology and specifically how it produces anti-ASCVD effects.  
A source of confusion regarding the pharmacological modulation of LDL-C and 
HDL-C is the measurement itself; the current cholesterol measurements included in a 
standard lipid panel do not capture the variability due to efficacy of lifestyle 
interventions and as a result are unable to provide for sensitive assessment of changes in 
ASCVD risk.  As will be reviewed in subsequent sections, improved understanding of 
ASCVD disease processes and lipoprotein biology as well as advances in technologies to 
characterize lipoprotein particle populations present in circulation can provide for 
additional insight into the effects of lifestyle intervention and potentially serve as 
sensitive assessors of intervention efficacy.  
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Cardiovascular disease and lipoprotein metabolism 
Cardiovascular disease is a general term encompassing a plethora of health 
complications many of which originate from atherosclerosis, an anglicized German term 
(“atherosklerose”) whose origins reside in the conjugation of the Greek words athērē 
(“groats/mealy”) and sklērōsis (“hardening”) (1). Thus, etymologically, atherosclerosis 
refers to the accumulation of foreign material (namely lipid constituents) within a blood 
vessel’s vasculature that hardens and form plaque deposits within the sub-endothelial 
space. Plaque accumulation decreases blood flow and increases systemic vascular 
resistance, increasing sheer stress on the endothelium and in accord with Poiseuille’s 
Law exponentially increases the amount of pressure needed to maintain blood flow. 
Additionally, the increased force required to produce blood flow through a plaque-laden 
vessel can lead to plaque rupture and clot release, causing a heart attack or stroke. The 
formation of atherosclerotic plaque is a complex phenomenon involving local, 
myocardial, and systemic inflammatory processes, and lipoproteins play a crucial, albeit 
somewhat paradoxical role in ASCVD (130).  
Canonical lipoprotein metabolism and ASCVD development 
Understanding the dynamics of canonical lipoprotein metabolism is important for 
understanding lipoproteins and ASCVD. The term “lipoproteins” refers to a diverse 
group of spherical and discoid particles composed of cholesterol, cholesterol esters (CE), 
triacylglycerides (TAG), phospholipids (PL), and apoproteins (Figure 1). Given that  
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Figure 1. General structure of lipoproteins. Note the lipoprotein core containing 
cholesterol ester and triacylglycerides, with the outer membrane composed of 
phospholipid, cholesterol, and apolipoproteins. Adapted from (100). 
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polar and nonpolar solutions remain relatively immiscible when mixed, lipoproteins 
provide lipid a means of conveyance through an aqueous environment (214). The  
amphipathic properties of phospholipids form a hydrophilic outer shell in combination of 
PL, unesterified cholesterol, and apoproteins surrounding a hydrophobic core of 
hydrophobic CE and TAG. Apolipoproteins assist in structural stabilization, lipid 
transfer, and enzymatic activities though specificity with receptors (80). The 
nomenclature for lipoproteins originates from studies that defined their densities through 
separation by isopycnic ultracentrifugation, leading to the eponymous categories of the 
TAG-rich very-low-density lipoproteins (VLDL) with a density of 0.96 to 1.006 g/ml, 
the intermediate-density lipoproteins (IDL) with a density of >1.006 to 1.019 g/ml, the 
relatively cholesterol-rich low-density lipoproteins (LDL) with a density range of >1.019 
to 1.063 g/ml, and protein-rich high-density lipoproteins (HDL) with a density range of 
>1.063 to 1.21 g/ml (Table 1). 
Human lipoprotein metabolism can be divided into forward lipid transport and 
reverse lipid transport, though this classification minimizes the diverse idiosyncrasies of 
lipoproteins. Nevertheless, cholesterol transported forward stems from two sources. The 
process of exogenous lipid transportation is initiated by chylomicron formation. The 
largest and most TAG-rich lipoprotein are chylomicrons which are formed in response to 
a fatty meal. Assembled by enterocytes bathed with digested nutrients from the diet, 
chylomicrons contain both diet-derived and lipid droplet-derived TAG and cholesterol, 
which are packaged in combination with an apolipoprotein B48 (apoB48) protein and 
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Table 1.  Major classes of lipoproteins. Triacylglycerides, TAG; cholesterol esters, CE; phospholipids, PL; cholesterol, Chol. 
Adapted from (171). 
Class Origin 
Major  
function 
Diameter 
(nm) 
Density 
(g/ml) 
Major 
protein 
Concentration 
in interstitial 
fluid 
Average composition by weight 
(%) 
TAG CE PL Chol Protein 
Chylomicrons Ileum 
Transport 
ingested fat 
and fat-
soluble 
vitamins 
200 -
1000 
<0.95 apoB48 absent 85 3 8 2 1 
VLDL Liver 
Transport 
synthesized 
TAG 
30 - 90 
0.95 -
1.006 
apoB100 absent 55 18 20 5 9 
LDL 
Lipolysis 
of VLDL 
Deliver 
cholesterol to 
cells 
22 - 28 
1.006 -
1.063 
apoB100 
~9% that in 
plasma 
10 50 29 11 20 
HDL 
Liver and 
Ileum 
Reverse 
cholesterol 
transport 
7 - 11 
1.063 -
1.21 
apoA1 
~20% that in 
plasma 
6 40 46 7 50 
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undergo exocytosis into the lymphatic lacteals adjacent to the enterocytes, entering 
lymphatic circulation and bypassing the liver. Chylomicrons ultimately enter vascular 
circulation at the thoracic duct. In general circulation chylomicrons acquire apoCII, 
apoCIII, and apoE from interactions with other lipoproteins. ApoCII is crucial for the 
activation of lipoprotein lipase (LPL), while apoCIII may delay the action of LPL and 
apoE is required for receptor-mediated hepatic uptake of chylomicron (39, 64, 98). 
Extrahepatic tissues expressing LPL, anchored by heparin sulfate proteoglycan (HSPG) 
chains, hydrolyze TAG on the surface of chylomicrons in a process critically-dependent 
on the presence of apoCII and glycosylphosphatidylinositol-anchored high-density 
lipoprotein binding protein 1 (GIPHBP-1)  (172, 228). The liberated fatty acids and 
monoacylglycerol passes through the cell membrane through diffusion or though fatty 
acid binding protein (FABP)-mediated transport or fatty acid translocase/cluster of 
determination 36 (FAT/CD36) where they are further metabolized for cellular energy or 
stored within lipid droplets following re-esterification into TAG (39, 80). As the 
chylomicron is depleted of its cargo the amphipathic monolayer becomes redundant. The 
surface PL and unesterified cholesterol become susceptible to dissociation and 
acquisition by HDL though the enzyme phospholipid transfer protein (PLTP). 
Eventually the chylomicron is reduced to a chylomicron remnant (CR) containing PL 
and apoB48 (172).  
The CR binds to hepatic sinusoids and is internalized by LDL receptors; if apoE 
is present the CR can also be internalized by the remnant receptor (LRP), where it is 
hydrolyzed into fatty acids and cholesterol. The liberated fatty acids and cholesterol are 
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stored in the liver but can be repackaged by the liver into a VLDL particle, assembled 
within a single apolipoprotein B100 (apoB100) scaffold. This process occurs within the 
hepatocytes’ endoplasmic reticulum. Upon assembly, VLDL is transported intracellular 
to the Golgi apparatus, which forms a Golgi vesicle that migrates to the cell membrane 
and undergoes exocytosis into general circulation. VLDL then travels through the 
circulation and is hydrolyzed by tissues expressing LPL in a process identical to the 
hydrolysis of chylomicrons. Exchange of lipid cargos with tissues and the exchange of 
apolipoproteins and redundant surfaces with other lipoproteins converts VLDL to IDL 
and eventually to LDL. In addition to density differences, VLDL and IDL retain apoE 
while LDL lacks apoE. LDL can continue to acquire and exchange lipids in the vascular 
compartment until apoB100 undergoes a conformational change in reference to the 
particle size, which is the impetus for recognition by ligand receptors in the liver (135). 
LDL is removed by LDL-receptor mediated endocytosis in the liver, a process that 
requires proprotein convertase subtilisin/kexin 9 (PCSK9) in order to mark the LDL 
receptor for degradation or recycling (230). In summary, forward cholesterol transport 
involves chylomicrons, VLDL, IDL, and LDL, and refers to the packaging and delivery 
of lipid cargo to muscle and adipose tissue.  
As previously mentioned, VLDL particles deliver their lipid cargo to tissues 
expressing LPL, a crucial function that allows the transportation of cholesterol and TAG 
to cells throughout the body. It is also well-established that LDL can transverse artery 
walls and enter the sub-endothelial space, where it can exchange lipid and, ideally, 
leaves the artery. Small LDL <25.5 nm in diameter may become trapped within the sub-
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endothelial space, increasing their likelihood for oxidation (5). This point is crucial 
because the retention and oxidation of LDL (oxLDL) is considered the progenitor of 
atherosclerosis (203). The presence of oxLDL triggers a cascade of inflammatory 
processes including monocyte infiltration into the sub-endothelial space and 
differentiation into macrophages. Upon engulfing multiple oxLDL, macrophages are 
transformed into foam cells. Foam cells and inflammatory cytokines trigger smooth 
muscle cell (SMC) migration into the sub-endothelial space, where they accumulate and 
form a fibrous cap. Interestingly, the SMC that populate or comprise the fibrous cap 
appear to be dysfunctional when compared to normal-phenotypic SMC as they lack 
functional ABCA1 and show uncharacteristic responses to normal stimuli such as 
vascular endothelial growth factor (VEGF) and nitric oxide (NO) (49). Macrophages can 
remain trapped within the fibrous cap die via necrosis rather than apoptosis with 
resultant uncontrolled release of cellular contents to form a necrotic core of lipid and 
cholesterol within the fibrous cap. Over time, the fibrous cap thins and may rupture, 
leading to a thrombus that can results in a heart attack or stroke (128-130). 
Reverse cholesterol transport (RCT) refers to the removal of lipid from both 
tissues and other lipoproteins and its transport back to the liver; this activity is performed 
exclusively by HDL. The act of sequestration by HDL on redundant surface lipids from 
hydrolyzed lipoproteins occurs through the enzymatic mechanisms of PLTP and 
lecithin:cholesterol acyltransferase (LCAT). The primary apolipoprotein on HDL, 
apolipoprotein A1 (apoA1) activates LCAT and is imperative for proper HDL function, 
to include RCT. ATP-binding cassette transporter member A1 (ABCA1) is also crucial 
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for cholesterol and phospholipid homeostasis; ABCA1 is expressed ubiquitously in 
human tissues and aids in the regulation of cellular cholesterol via its exchange activity 
with HDL (205). HDL may also remove cholesterol and TAG found within tissues such 
as capillaries and macrophages through the action of LCAT and the transporter ABCA1 
(46, 48). Additionally, CE-rich HDL can exchange cholesterol for TAG from apoB-
containing lipoproteins through the action of at liver, HDL are internalized by scavenger 
receptor, type B, class 1 (SR-B1) for hepatic hydrolysis of CE. Smaller HDL, for 
example an HDL containing a single apoA1 moiety or delipidated HDL, are not 
internalized by SR-B1 and re-enter circulation (116, 127, 212). Hepatic lipase (HL) may 
also hydrolyze surface lipids of HDL, resulting in smaller HDL particles that re-enter 
circulation.  
In summary, lipoproteins such as chylomicrons, VLDL, and LDL deliver cargo 
from the diet and from storage to peripheral tissues while other lipoproteins, namely 
HDL, exchange lipid and cholesterol from forward-delivering apoB-containing 
lipoproteins in order to return these materials to the liver (Figure 2). In the classical 
model of ASCVD, trapped lipoprotein and their cargo become oxidized, triggering a 
cascade of inflammatory processes that lead to an accumulation of lipid and SMC, which 
can develop into atherosclerosis. 
Classical assessment of lipoproteins and their relationship to ASCVD 
The classical assessment of lipoproteins involves quantification of TC, TAG, 
LDL-C, and HDL-C. Total cholesterol is measured enzymatically by hydrolyzing 
cholesterol esters and then oxidizing the freed cholesterol, forming the by-product  
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Figure 2. Summary of lipoprotein metabolism. Adapted from (224).  
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hydrogen peroxide (H2O2), which is proportional to the amount of cholesterol oxidized 
(32, 177, 179). The peroxidase reaction is coupled with a color-producing chromophore;  
absorbance of this color is measured at 500 nm which determines the quantity of H2O2 
present, thus the amount of cholesterol present. A similar enzymatic method is used to 
quantify TAG, hydrolyzing TAG to produce glycerol, then oxidizing the free glycerol to 
form a proportional amount of H2O2, which is coupled to the same chromophore 
previously mentioned and absorbance is measured at an identical wavelength to 
determine quantity. Finally, HDL is measured using a direct method, with apoB-
containing lipoproteins precipitated from the sample using sulfated alpha-cyclodextrin 
and magnesium, forming a complex with apoB-containing lipoproteins. The lipoproteins 
remaining free in solution are non-apoB-containing lipoproteins and presumed to be 
exclusively HDL. Cholesterol in the fraction is measured enzymatically (32).  
LDL cholesterol (LDL-C) can be measured directly or indirectly, with indirect 
methods being the most common (32). Direct methods are not typically utilized in the 
clinical setting due to cost and specificity of required instrumentation (154). The most 
frequently used indirect method calculates LDL-C following quantification of TC, TAG, 
and HDL-C by use of the Freidewald equation (32, 65): 
[LDL-Ccalc] = [TC] − [HDL-C] − [TG]/5 
The Freidewald equation estimates LDL-C using the assumption that LDL-C can be 
calculated by TC minus the presence of HDL-C, minus TAG divided by 5 to account for 
the presence of VLDL. It has been determined that TAG levels >4000 mg/L (>400 
mg/dl) will distort LDL-C measurements estimated from Freidewald equation (154).  
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The method of enzymatically quantifying TC, TAG and HDL-C, then estimating 
LDL-C is commonly referred to as a “cholesterol panel” in the healthcare community 
(73). It is also important to note that this method is the only standardized method for 
assessing lipoprotein cholesterol concentrations. It does not characterize lipoprotein 
physical properties including composition other than cholesterol content. This 
standardized clinical methodology is what is used to assess risk at the population level. 
Its ability to assess the efficacy of TC and LDL-C lowering is well documented. The 
efficacy of this technology to assess risk reduction due to artificial HDL-C raising 
therapies is less certain. The interpretation of a cholesterol panel based on the Adult 
Treatment Panel III by the National Cholesterol Education Program (NCEP) is provided 
(Table 2). 
Other methodologies 
Although national public health agencies utilize the aforementioned clinical 
assessment method for lipoprotein cholesterol, novel and increasingly accurate processes 
to capture more information than cholesterol content have been developed that range 
from floatation/density characterization to nuclear magnetic resonance (NMR). 
Lipoproteins are increasingly resolved into specific subfractions whose components are 
being quantified via immunoassays, gradient gel electrophoresis, ion mobility, and NMR 
in research in order to describe the particle itself in addition to its cargo. 
Gel electrophoresis utilizes size-exclusion or charge to separate lipoproteins that, 
typically, have been separated into broad density subfractions, i.e. VLDL, LDL and 
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Cholesterol Panel Guidelines 
LDL-cholesterol (mg/dl) 
Optimal < 100 
Near optimal 100 to 129 
Borderline high 130 to 159 
High 160 to 189 
Very high ≥ 190 
Total cholesterol (mg/dl) 
Desirable < 200 
Borderline high 200 to 239 
High ≥ 240 
HDL-cholesterol (mg/dl) 
Low < 40 
Optimal ≥ 60 
 
Table 2. Cholesterol panel guidelines. Displays ASCVD-risk using results from a classic 
cholesterol panel. Adapted from (162). 
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HDL, by preparatory ultracentrifugation prior to analysis (5). Immunoassays utilizes 
specific antibodies for various apolipoproteins to differentiate lipoproteins (such as apoB  
within LDL and apoA1 within HDL). Notably, apoB-containing lipoproteins contain one 
apoB protein per particle and this allows absolute particle number to be determined by 
immunoassay. The same situation does not exist in HDL as particles floating in the HDL 
density range can contain one or several apoA1 proteins as well as containing no apoA1 
protein; albeity as we will discover non-apoA1-containing HDL are dysfunctional in 
RCT and can be proinflamatory (177, 179). Two-dimensional gradient gel 
electrophoresis separates HDL using electrostatic charges or density gradient 
centrifugation followed by polyacrylamide gel particle size separation. Visualization of 
HDL particles is achieved through staining or blotting with antibodies (170, 177). 
Another separation methodology is ion mobility; this method also requires 
ultracentrifugation to separate HDL from other lipoproteins and albumin prior to 
separation by size in a voltage gradient. Particles are condensed and quantified by light 
scattering (31, 177). Nuclear magnetic resonance spectroscopy relies on magnetic 
properties inherent in lipoprotein particles that are based on size and which produce 
distinct signals when exposed to a magnetic field. In this analysis magnetic resonance is 
proportional to the methyl group protons of lipids that comprise each lipoprotein particle 
and so allows concentration of subclasses to be determined (160, 177).  
In the last 10 years, high-performance lipoprotein density profiling (HPLDP) has 
gained popularity (119). Based on one of the earliest and most high-resolution 
methodologies of analytic ultracentrifugation, HPLDP embodies technical changes that 
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reduce analysis time and simplify subfraction imaging. This method allows for rapid (six 
hours) separation of lipoprotein subfractions using ultracentrifugation, which have been 
incubated with a fluorophore (101) . Using a salt solution that forms a density gradient 
upon centrifugation, the lipoprotein subfractions are visualized by the use of a light 
source that excites only fluorophore that has partitioned into the lipoprotein surface. 
Subfraction density distribution is imaged using specific filters that match the excitation 
and emission paramenters of the fluorophore. The image of the emitted light is captured 
using a CCD camera. The image is analyzed by first converting the image into a pixel 
matrix whose values correspond to fluorescent intensity/quantity. This relationship 
allows for lipoprotein particle mass quantification. This method is rapid (<6 hours for 
gradient formation) and inexpensive compared to other methods.   
Lipoprotein cholesterol, ASCVD risk, and current treatment guidelines 
As previously discussed, clinical methods used to assess ASCVD risk reveal only 
the Chol and TAG content of lipoproteins, revealing little about their structure or 
function. Nevertheless, the ranges for lipoprotein cholesterol outlined in Table 2 are the 
primary means of classifying ASCVD-risk in the healthcare setting. These guidelines 
originated from a plethora of research over the past 75 years regarding a relationship 
between lipoprotein cholesterol and ASCVD mortality (6, 152, 199).  
The most agreed upon relationship between lipoprotein cholesterol and ASCVD 
risk is that LDL-C is positively-correlated with ASCVD mortality, while HDL-C is 
inversely-correlated with ASCVD mortality (200, 209). Reducing LDL-C is as simple as 
taking a medication due to the development of 3-hydroxy-3-methylglutaryl-coenzyme A 
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(HMG-CoA) reductase inhibitors, generically referred to as statins, which effectively 
limit cellular cholesterol synthesis while upregulating LDL-receptor expression, 
resulting in an increase in hepatic clearance of LDL-C (33). Statins also may modestly 
raise HDL-C in some patients (26). Increasing HDL-C through medication that inhibits 
the CETP enzyme can increase HDL-C by up to 80% (11).  
In the time periods of 1988–1994 and 2007–2010, the use of cholesterol-
lowering medication in the United States significantly increased from 5% to 25% in men 
and 6% to 21% in women (117). In adults aged 40-64, statin use increased from 4% to 
19% and adults aged 65–74 statin use increased 10% to 39% (117). Correspondingly, the 
prevalence of elevated LDL–C decreased significantly from 59% of adults having 
elevated LDL-C in 1976–1980 to 42% in 1988–1994, which further decreased to only 
27% of adults having elevated LDL-C in 2007–2010 (117). Additionally, several HDL-C 
raising drugs are currently in clinical trial (110).  
Despite the improvements in LDL-C and HDL-C, the number one symptom of 
ASCVD remains sudden death due to cardiac arrest and is responsible for 50% of all 
ASCVD deaths (182, 231). Furthermore, 50% of those who die from ASCVD have 
LDL-C equivalent to or below 100 mg/dl, a concentration associated with significant 
reduction in risk of ASCVD mortality. In addition approximately half of those who 
suffer a clinical ASCVD event have  HDL-C greater than>40 mg/dl, a concentration 
with reduced ASCVD mortality risk (18, 187). Adding to the confusion, several studies 
examining the efficacy of CETP-inhibitors to reduce ASCVD risk by increasing HDL-C 
were  ended early due to a statistically significant increase in mortality attributed to off-
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target effects  (11) or lack of efficacy in risk reduction. This is seems that  medical 
interventions can successfully reduce LDL-C and associated ASCVD risk additional 
information is needed to understand whether HDL-C can be used to accurately assess 
residual risk or whether other techniques would better serve this purpose.  
Lipoprotein diameter and ASCVD risk 
Not assessed by cholesterol panels, the atherogenicity of lipoproteins is directly 
related to time spent in circulation (218). The longer particles remain in circulation, the 
greater their susceptibility to oxidization; for example, delayed clearance of LDL results 
in more metabolic interactions, reducing particle diameter and increasing atherogenicity 
(217, 218). Similarly, HDL exhibits functions beyond RCT that appear to be 
significantly related to its diameter. Thus, alternate means of measuring the diameter of 
lipoproteins have emerged as a prognostic indicator for assessing ASCVD risk (42, 69, 
145).  
Low-density lipoproteins classified as small and dense (sdLDL) are ~22 nm and 
d = 1.050-1.063 g/ml, appear to increase ASCVD risk due to the ease at which they enter 
the sub-endothelial space and their increased susceptability to oxidization (99, 118, 211). 
This subfraction is reportedly associated with a three-fold increase in risk of myocardial 
infarction (5). Additionally, patients with coronary artery disease exhibit sdLDL, which 
is inversely correlated to HDL-C and apoA1 and positively correlated to prevalence of 
smaller HDL particles (< 10.5 nm)(25). A shift in the diameter of LDL from small (~22 
nm) to large (~26 nm) is considered beneficial for ASCVD risk reduction (195). In 
people free ofASCVD, large LDL are common while sdLDL are not (202). These 
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studies demonstrate the heterogenity of LDL size and emphasize the need to classify 
LDL by not only LDL-C but also LDL diameter (71).   
Equally significant, HDL particles of different diameters are associated with 
varying ASCVD risk (57). In general, larger HDL-2 particles, 10.5 to 14.5 nm, are 
associated with a decrease in ASCVD risk, while smaller HDL-3 particles , 7.7 to 10.5 
nm,  are associated with increased ASCVD-risk (93, 99). Using NMR and gel 
electrophoresis, Harchaoui et al. (57) found a strong association with small HDL 
particles and metabolic syndrome. Kontush et al. (177) have reported that large diameter 
HDL ( > 10.5 nm) are strongly associated with HDL-C and are thus indicative of 
reduced ASCVD risk. Furthermore, a recent study by Hussein et al. (93) demonstrated a 
defect in the antioxidant capacity of HDL-3 in patients exhibiting familial 
hypercholesterolemia. Taken together, these studies demonstrate a similar association 
between larger diameter HDL and reduced ASCVD risk. 
High-density lipoproteins: functions beyond reverse cholesterol transport 
An emerging charateristic of HDL not assessed in a cholesterol panel is its anti-
inflammatory, anti-oxidant, anti-apoptotic, anti-glycation, and anti-thrombotic capacity 
(196). As previously stated, HDL can attenuate the effects of oxLDL through RCT, 
mediated by ABCA1  translocation of internal cholesterol stores, or from oxLDL from 
within the sub-endothelial space, to the outer cellular membrane for acquisition by HDL 
(178).  
Another action of HDL in the reduction of oxLDL is through the action of 
paraoxonase-1 (PON1) (53). Synthesized by the liver, PON1 activity has been shown to 
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reduce lipid peroxide accumulation and low PON1 activity despite normal HDL-C was 
shown  in ASCVD patients (192, 197). Interestingly, the anti-oxidant characteristics of 
HDL mediated by PON1 appear to reduce LDL glycosylation, an independent risk factor 
for developing ASCVD; this phenomena is frequently observed in patients with type 2 
diabetes and metabolic syndrome (MetS) (47, 225). High-density lipoproteins can also 
reduce tumor necrosis factor-α mediated expression of adhesion molecules commonly 
associated with aortic endothelial cells such as vascular cell adhesion protein-1 (VCAM-
1) and intracellular adhesion molecule-1 (ICAM-1) (178). These adhesion proteins are 
strongly associated with hyperlipidemia and acute coronary syndrome (23).  
Paradoxically, HDL may exhibit pro-inflammatory characteristics, including 
reduced RCT from macrophages and the production of pro-oxidants, especially in 
patients with MetS and diabetes (43, 136, 178, 190). In subjects who have ST segment 
elevation myocardial infarction (STEMI), HDL appears to be saturated with serum 
amyloid A (SAA), an acute phase reactant and marker of inflammation, and exhibits 
attenuated antioxidant capabilities compared to subjects who have not had STEMI (169). 
This supports the hypothesis that HDL may be rendered dysfunctional due to chronic 
inflammation that may damage or impair the action of apoA1 (178). As demonstrated in 
the pharmokinteics of CETP-inhibitors, HDL may also lack the ability to transfer CE 
due to inhibition of CETP, leading to a reduced capacity to interact with SR-B1 and 
reduced RCT, which may result in elevated HDL-C (178). Unfortunately, functional 
HDL is indistinguishable from dysfunctional HDL when measuring HDL-C.  
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These anti- and pro-atherogenic characteristics of HDL underline the diverse 
nature of the particle depending on the influence of the environment, which are not 
assessed in a cholesterol panel.   
Modifiable lifestyle factors and ASCVD risk 
It has been estimated that 90% of ASCVD is preventable and related directly to 
lifestyle factors, primarily through poor dietary and physical activity habits (139, 143). 
In an effort to reduce ASCVD risk by capitalizing on these modifiable risk factors, 
guidance by international organizations has focused on modifying diet and physical 
activity. It is important to note that these intervention strategies are evaluated using 
changes in ASCVD rates and cholesterol panel outcomes.  
Dietary recommendations to reduce ASCVD risk 
Traditional dietary guidelines for the prevention of ASCVD are focused on 
reducing total fat intake and increasing carbohydrate intake, and were established from 
strong correlations observed in epidemiological studies to relate diet composition to 
ASCVD mortality rates (59, 96, 120, 200). Nutrient targets to reduce ASCVD are 
commonly presented as food-based guidelines as opposed to individualized nutrition 
strategies; these guidelines include replacing saturated fats with unsaturated fats, 
increasing consumption of low-fat dairy products, whole-grain cereals, fruits, vegetables, 
and fish, while avoiding fatty meat, red meat products, added salt, and added sugar 
(173).  
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Fat intake 
The findings of the Seven Countries Study by Ancel Keys, in addition to other 
ASCVD epidemiological studies, revealed strong-correlations between saturated fat 
intake (SFA) and ASCVD (58, 108, 133, 144, 200, 220). Reducing fat intake is a 
primary recommendation for ASCVD risk reduction (61, 149, 194, 213). The central 
hypothesis regarding fat intake reduction to reduce serum cholesterol has been 
challenged as more studies fail to reaffirm the association with fat intake and ASCVD 
risk (117, 183). The biochemical processes that related to the effect of SFA and ASCVD 
are more complex than previously thought; for example, SFA stimulates ABCA1 
expression which increases HDL-C and TC, while polyunsaturated fatty acid (PUFA) 
appears to diminish ABCA1 expression (137). Vafeiadou et al. found that replacing SFA 
with monounsaturated fatty acids or PUFA increased HDL-C and TC but did not impact 
vascular function (213). The central hypothesis regarding fat intake reduction to reduce 
serum cholesterol continues to be challenged as more studies fail to reaffirm the 
association with fat intake and ASCVD risk (117, 183).  
A seminal analysis by Hu et al. using the Nurses’ Health Study found the risk for 
coronary heart disease is directly related with total fat intake (89). However, upon 
controlling for smoking, alcohol use, and exercise, these associations no longer were 
significant. Another study which revisited subjects who participated in the 1995 Nurses’ 
Health Study found only PUFA consumption remained directly correlated with an 
increased risk for coronary heart disease, not total fat intake (159). Further complicating 
matters, the Woman’s Health Initiative Randomized Controlled Dietary Modification 
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Trial found that reducing fat intake from 37.0% of total energy intake to 28.8% of total 
energy intake over the course of eight years did not reduce ASCVD risk compared to 
controls (88). Another study found a reduction in ASCVD risk with higher fat intakes of 
PUFA and MUFA, while ASCVD risk increased with SFA intake associated with 
pastries and processed goods (79). Finally, two meta-analysis found no evidence to 
continue to recommend reduced fat intake or reduced SAT fat intake for the prevention 
of ASCVD (36, 194). In the first, Chowdhury et al. (35) reviewed 32 studies on fatty 
acid consumption and ASCVD risk and determined that no evidence exists to support the 
consumption of PUFA in place SFA to reduce ASCVD risk, though total fat intake was 
not assessed (35). In the second, Siri-Tarino et al. looked at 21 studies that included 
ranges from 5 to 23 years to determine rates of ASCVD and diet composition; the 
authors concluded that no association existed between dietary SFA intake and ASCVD 
risk (194).  Together, these studies reveal a conflicted scientific consensus on the impact 
of total and SFA on ASCVD risk.      
Calorie restriction 
Although a myriad of dietary modifications exists to reduce ASCVD risk in both 
the scientific community and popular press, the common denominator is unquestionably 
calorie restriction (CalR). When basal dietary caloric intake is reduced by 25%, ASCVD 
risk is reduced by up to 20% (122). In support of this finding, isocaloric diets with 
differing macronutrient ratios have been found to produce identical body fat reduction, 
reduced ASCVD risk, and improved markers of inflammation (50, 185). Due et al. 
compared the effectiveness of three diets with varying percentages of fat and 
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carbohydrates (51). Although fat composition varied by 15% of total calories, total 
calories were identical and no markers for ASCVD varied between groups. Other 
physiological processes may be influenced by CalR that contribute to the effectiveness 
of CalR for ASCVD risk reduction. The reader is directed to a phenomenal review on 
the topic by Weiss and Fontana (221).   
Adherence to dietary recommendations 
Adherence to food-based dietary recommendations such the Healthy Eating 
Index is associated with reduced ASCVD-risk (173). “Healthy Eating Indexes” are 
commonly used to assess the compliance of a specific population to dietary guidelines, 
which can be compared to rates of ASCVD. As such, increasing compliance with a 
number of healthy eating indexes (Alternative Healthy Eating Index (AHEI-2000), 
Alternative Mediterranean Diet (AMED), or Dietary Approaches to Stop Hypertension 
(DASH)) can reduce ASCVD risk by up to 20% (198). These indexes follow similar 
guidance, advocating consuming less animal product while increasing consumption of 
nuts, seeds, fruits, vegetables, vegetable oils, and whole grains (34, 67, 68).  
Interestingly, Americans have generally met these dietary recommendations, improving 
their healthy eating index scores (assessed using the HEI-2010) by more than 20% since 
1999 (Figure 3) (144, 219). The upward trend in healthy diet scores is attributed to the 
decline in total fat intake from 36.9% to 33.4% in men and 36.1% to 33.8% in women; 
not surprising, an 80% increase in the consumption of carbohydrates accompanied the 
reduction in total fat intake (19, 86). The percentage of adults meeting reduced saturated-
fat intake guidelines also increased significantly from 1976–1980 to 1988–1994 (from  
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Figure 3. Healthy Eating Index 2010. Adherence of US population ≥ 2 years of age to 
the 2010 Healthy Eating Index. Adapted from (219). 
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25% to 41%), which has held constant up to 2010. Additionally, since 1979 total 
saturated fat intake has steadily decreased (19, 117). Despite improving diet scores and 
meeting macronutrient guidelines, energy intake (kcal/d) has increased significantly in 
the US; since 1971 energy intake has increased 22% in women (from 1542 to 1886 
kcals/d) and 10% in US men (from 2450 to 2693 kcal/d) (150).  
Assessment of body composition 
The gold standard for body composition measurements is dual energy x-ray 
absorptiometry (DEXA) (91, 180). Using two distinct energy levels, 40 and 70 keV, 
photons pass through subjects’ body and can distinguish fat and non-fat tissue (2). 
Compute models interpret this data and quantify not only body fat percentage but also 
the location and quantity of body fat in various anatomical regions. Advantages of using 
DEXA as opposed to classic body composition measurements such as eight for height or 
skinfold thickness measurement, is the precision and repeatability of these measurements 
and the ability to combine DEXA information recorded indifferent locations or using 
different machines when proper validation of measurements are made (2, 91). 
Exercise prescription and assessment techniques 
Multiple means of assessing the efficacy of exercise interventions exist, but 
maximal aerobic power or V̇O2 max (VO2 max) is “accepted as the criterion 
measurement of cardiorespiratory function” (140).  Maximal aerobic power is 
considered the best measurement of cardiovascular functional limits and predicts 
mortality from all causes in health and unhealthy individuals (17, 82, 153, 181). 
 
 
 
 
  
27 
The Fick Equation outlines the primary determinants of VO2 max:  
V̇O2 max = Q̇ x (CaO2 – CvO2) 
Where Q̇ is cardiac output (CO), expressed as liters of blood per minute (L blood x  
min-1) and CaO2 – CvO2 is arterial-venous oxygen difference (A-V O2 diff), expressed as 
milliliters of oxygen per liter of blood (ml O2 x L blood
-1) (140). This measurement is 
specifically referred to as “absolute VO2 max” and can be adjusted to include body 
weight of the subject as means to compare VO2 max measurements.  
One such modification to absolute maximal aerobic power is “relative VO2 max” 
which is expressed as milliliters of oxygen consumed per minute per kilogram body 
weight (ml O2 x min
-1 x kg-1). This measurement is most frequently used in literature to 
compare VO2 max measurements between subjects. A more accurate modification is 
“relative lean body mass VO2 max” which is expressed as milliliters oxygen consumed 
per minute per kilogram lean body mass (LBM) or non-fat mass (ml O2 x min
-1 x kg 
LBM-1).  This modification less variable because it is not influenced by fat or weight 
reduction commonly associated with diet and exercise. Albeit changes in LBM can 
occur. Nevertheless, it allows for an accurate assessment of absolute VO2 expressed as a 
ratio to LBM. At the time of this writing, definitive norms for relative LBM VO2 max 
are virtually nonexistent; most research continues to report VO2 max expressed as a 
percent change from baseline using relative VO2 max (7). Note that using relative VO2 
max can be misleading. For example, subjects may lose mass and not improve their 
absolute VO2 max, but will improve their relative VO2 max since it is expressed per 
kilogram body weight, misleading the researcher into reporting improvements in 
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cardiorespiratory fitness despite there being none. Since relative VO2 max is inextricably 
influenced by body composition changes, efforts to use relative LBM VO2 max in place 
of relative VO2 max have begun. Relative LBM VO2 max may change in response to 
changes in LBM and/or VO2 max and is unbiased by changes in non-oxygen consuming 
tissues. Alternately, absolute VO2 max indicates true changes to cardiorespiratory 
function albeit without the influence of body composition. The problem is absolute VO2 
max doesn’t account for body composition differences between subjects: two people 
may have identical absolute VO2 max assessments but be at much different levels of 
fitness if one weighs 50 kg and the other weighs 100 kg. Regardless, both relative LBM 
VO2 max and absolute VO2 max are more accurate than relative VO2 max in regards to 
assessing the O2 consumption of working tissues, especially when used for comparing 
baseline and final measurements of lifestyle interventions that are known to impact body 
weight and composition.  
Differences in VO2 max between male and female genders is well-documented 
(20, 112). Men typically have a 40% greater absolute VO2 max than women, which is 
reduced to a 10% difference when relative LBM VO2 max is used (20). In addition to 
difference with lean body mass, the influence of androgens on hemoglobin production 
also is responsible for the disparity of oxygen-carrying capacity between sexes (20). 
Interestingly, the ability to improve VO2 max is virtually identical between males and 
females; training adaptations can result in a 20% increase in VO2 max capacity (20). 
Age also influences VO2 max. Between ages 20 and 65, VO2 max declines 
approximately 30% (20). Referring to the Fick Equation, the decrease in VO2 max is 
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attributable to reduced maximal heart rate and reduced stroke volume, as well as reduced 
power output caused by a decline in muscle mass, especially adults 65 years of age or 
older (20). 
Traditional, individualized exercise prescription begins with an absolute VO2 
max measurement converted into a relative VO2 max.  With this value established, target 
heart rates or VO2 max goals are prescribed, the latter as a percentage of baseline 
relative VO2 max. Although a maximal VO2 max test can be conducted where the 
subject exercises to failure, various health and safety concerns make sub-maximal 
testing an attractive alternative, especially in at-risk population such as subjects with 
ASCVD (140). Common sub-maximal VO2 tests include the Bruce Protocol, which is 
covered in extensive detail elsewhere (21). These sub-maximal tests utilize algorithms to 
predict absolute VO2 max with acceptable results (76, 140). Once a baseline VO2 max is 
established, exercise prescription as a percentage of relative VO2 max can be 
determined, using the subject’s heart rate as a means of self-assessing exercise intensity. 
In a laboratory, exercising at a percent of VO2 max can be monitored using O2 
consumption or other means.  
Exercise intensity is commonly expressed as a percentage of relative VO2 max or 
as multiples of resting metabolic rate or metabolic equivalents (METs), which at rest is 
expressed as 3.5 ml O2/kg/min (97). Both are compared for reference in Table 3. 
Exercise intensity is crucial for effective exercise intervention and the subsequent 
reduction in CVD risk. In fact, the need to engage in high-intensity, peak or near peak 
VO2 max (at or above 85% relative VO2 max) activities to reduce ASCVD risk rather  
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Table 3. Five-level classification of physical activity based on exercise intensity. 
Adapted from (138). 
 
 
 
 
 
 
 
 
 
 
 
Five-Level Classification of Physical Activity Based on Energy Intensity 
 
Energy Expenditurea 
L x min-1 ml x kg-1 x min-1 METs 
Men 
Light 0.40-0.99 6.1-15.2 1.6-3.9 
Moderate 1.00-1.49 15.3-22.9 4.0-5.9 
Heavy 1.50-1.99 23.0-30.6 6.0-7.9 
Very Heavy 2.00-2.49 30.7-38.3 8.0-9.9 
Unduly Heavy ≥2.50 ≥38.4 ≥10.0 
Women 
Light 0.30-0.69 5.4-12.5 1.2-2.7 
Moderate 0.70-1.09 12.6-19.8 2.8-4.3 
Heavy 1.10-1.49 19.9-27.1 4.4-5.9 
Very Heavy 1.50-1.89 27.2-34.4 6.0-7.5 
Unduly Heavy ≥38.4 ≥38.4 ≥38.4 
aL x min-1 based on 5 kcal per liter of O2; ml x kg
-1x min-1 based on 65 kg man and 55 
kg woman; one MET equals the average resting oxygen consumption (250 ml x min-1 
for men, 200 ml x min-1 for women) 
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than simply engaging in low to moderate intensity physical activity has recently been 
discussed (188, 223). Sassen et al. (188) found an inverse relationship between engaging 
in peak relative VO2 max exercise (assessed as METs) and ASCVD risk factors, 
concluding that engaging in high-intensity exercise (>6 METs), not low-intensity 
physical activity (<4 METs), is primarily responsible for ASCVD risk reduction. 
Additionally, engaging in activity that produced peak oxygen uptake was attributed to 
approximately 78% of ASCVD risk reduction derived from exercise (188). Supporting 
this finding, a meta-analysis by Williams et al. demonstrated a large statistical difference 
in the relative risk reduction for ASCVD when subjects engage in physical activity 
versus engaging in physical fitness, expressed as person-years engaged in physical 
activity (223). The authors determined that relative to the least fit or active percentiles, 
the relative risk reduction for CVD is significantly greater for fitness than physical 
activity and is precipitous up until the 25th percentile for fitness.   
Exercise recommendations for ASCVD risk reduction 
Exercise in almost any capacity and frequency reduces the risk of mortality 
across most ages, diseases, and medical conditions (12). Accordingly, sedentary 
behavior is directly related to increased mortality (52, 102). However, evaluation of the 
effectiveness for exercise on ASCVD risk has been limited to studies assessing changes 
in LDL-C and HDL-C (41, 95, 113). Nonetheless, the effect of exercise on lipoprotein 
cholesterol is variable and appears highly individualized depending on, modality, 
intensity, duration, and frequency of exercise as well as the subject’s anthropometrics.  
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The effect of exercise on lipoprotein cholesterol measured by lipid panel 
It is widely accepted that regular exercise at a moderate-intensity reduces LDL-C 
and raises HDL-C compared to sedentary controls (3, 27, 124, 125, 146). Exercise is 
recommended by the National Cholesterol Education Program to reduce ASCVD risk 
(156). Mechanistically, an increased turnover of lipid substrates through increased LPL 
activity in adipose and skeletal muscle is thought to reduce ASCVD risk (204). 
Increased LPL activity may also reduce the total amount of chylomicrons and VLDL in 
cirulation, reducing TAG concentration (204). Exercise may also increase HDL-C 
through decreased HL activity, reducing HDL clearance (204).  
Complicating the effects of exercise on lipoproteins is the inherent variability of 
time, duration, and type of activity that is possible. Exercise adaptations depend greatly 
on 1) the subject’s previous exposure to exercise, and 2) the modality, intensity, 
duration, and frequency of training (103, 104, 106, 164, 210). Finally, cessation/non-
adherence to physical exercise and the confounding variables of anabolic activities such 
as strength training versus catabolic activities such as cardiovascular activities, affect 
ASCVD risk in a myriad of different ways (14, 15). Nevertheless, the following sections 
summarize the most current research and national guidelines regarding exercise and its 
effects on lipoproteins.   
Acute endurance exercise 
Acute endurance exercise refers to a single bout of aerobic exercise. A single 
bout of endurance exercise has been shown to improve blood lipids (54). Yu et al. used 
NMR and a cholesterol panel to measure acute changes in lipoprotein cholesterol 
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concentrations and subclass distribution in elite athletes who participated in a triathlon 
(229). After the triathlon, sdLDL decreased by 62% compared to baseline, while small 
HDL decreased by 16%.  The authors also noted a 7% decrease in TC, 23% decrease in 
LDL-C, and 30% increase in HDL-C (229).  In untrained individuals, acute exercise of 
high-intensity produces identical changes in LDL-C observed in elite athletes (115, 155). 
Kraus et al. found that acute, high-intensity exercise (>85% relative VO2 max) can 
slightly increase HDL-C, but dramatically increased LDL particle size (115).  
Alternately, Nelson and Horowitz (155) found that acute exercise in sedentary 
obese and mildly dyslipidemic individuals had no effect on TC, LDL-C and HDL-C. 
Despite the lack of change in lipid panel cholesterol values with single bout of exercise, 
the authors found that for three days following the exercise session, insulin sensitivity 
was identical to trained exercisers, dramatically reducing ASCVD risk. Crouse et al. (40) 
on the other hand found that HDL-2 cholesterol rose with training, while HDL-3 
cholesterol was lower. Finally, Greene et al. (78) observed increases in HDL 
subfractions without changes in HDL-C following 12 weeks of progressive endurance 
training. 
Summarizing the effects of acute exercise on lipoprotein cholesterol, despite 
individual variability in response to an exercise training session and the subsequent 
heterogeneity observed with lipoprotein cholesterol, indicators of ASCVD risk are 
improved with participation in acute exercise programs. 
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Chronic endurance exercise 
Chronic endurance exercise in this document refers to habitual exercise occurring 
over the course of a minimum of eight weeks.  Chronic endurance exercise, regardless of 
intensity, increases HDL-C and reduces LDL-C (72). Typically, studies demonstrate an 
increase in the more cardio-protective HDL2 subfraction, while sdLDL concentrations 
decrease in conjunction with increased concentrations of larger diameter LDL (85). 
Additionally, chronic exercise reduces plasma TG concentration in a dose-dependent 
manner, with changes that can vary from immediately post-exercise up to a few days 
later (60). These repeated bouts of exercise alter adipose and muscle tissue blood flow 
and improve utilization of fatty acids for fuel (87). As demonstrated by Horowitz and 
Klein (87), intramuscular TG increase as plasma TG decrease, distinguishing active 
individuals from sedentary overweight individuals with increased intramuscular TG. The 
adaptations associated with chronic endurance training may explain the changes seen in 
cholesterol panels. In elderly subjects, although exercise may not produce marked 
statistical changes in lipoprotein profiles, it significantly reduces the susceptibility of 
LDL subfractions to oxidation, which is a risk for developing atherosclerosis (142). A 
recent meta-analysis of nine randomized controlled trials on obese and overweight adults 
seemed to concur with the previous study by demonstrating that aerobic exercise had 
little effect on TAG, TC, LDL-C and HDL-C (22).   
Summarizing the available research, any endurance training improves blood 
lipids, with an initial reduction in TAG and sdLDL, while increasing TAG-rich LDL. 
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These changes may occur in the absence of changes to LDL-C concentrations and would 
be overlooked by standard clinical blood lipid measurements.  
Acute and chronic strength training 
Strength training involves progressive resistance against a muscle to induce 
muscular contraction, which is beneficial for muscular endurance, strength, and injury 
prevention (63) There is contradicting evidence thought regarding the effect of strength 
training, either acute or chronic, on lipoprotein cholesterol. Historically, strength-based 
exercise was deemed to be ineffective in blood lipid modulation, and has even been 
suggested as deleterious to ASCVD risk, however no deleterious effects were found in a 
small study of 27 previously untrained men that directly compared strength, endurance, 
and combined training (72). Studies using animal models found no untoward effects of 
strength training alone on lipoproteins, but found that testosterone injections combined 
with strength training lowered HDL-C (92). Several studies conducted in the mid-1980s 
and 1990s used lipid panel outcomes to demonstrate that chronic resistance training in 
the absence of diet modification could improve blood lipids (66, 75, 92). A meta-
analysis on 29 studies conducted by Kelly and Kelly (104) found reductions of 2.7% for 
TC, 11.6% for TC/HDL-C, and 6.4% for TAG when subjects performed strength-based 
exercise. When combined with strength training, diet modification does not appear to 
enhance the effects of strength training alone on lipoprotein cholesterol levels (148). 
Interestingly, a 2013 report noted that strength training improved HDL functionality in 
regards to its antioxidant abilities compared to sedentary controls (175).  
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In summary, strength training appears to have a favorable impact on reducing 
ASCVD risk, either through reducing LDL-C and increasing HDL antioxidant capacity, 
or through other means not assessed via lipoprotein cholesterol panels.  
Concurrent training 
It should be noted that although aerobic and strength training activities performed 
individually produce an improved lipid profile, a combination of aerobic and strength 
training activities achieves the same results but more rapidly (146). A meta-analysis of 
six studies at least four weeks in duration found that diet and exercise combined 
produced greater reductions in LDL-C while increasing HDL-C, compared to either diet 
or exercise alone (107). It should be also be noted that studies that include diet and 
exercise typically result in weight loss; body fat reduction results in reduced LDL-C and 
may also increase HDL-C if exercise is included in the intervention (216). Alternately, 
Varady et al. found that combined diet and endurance exercise had no effect on LDL-C 
and LDL particle size in obese, untrained women (215). Finally, a seminal study by 
Lefvere et al. (122) found that when non-obese healthy individuals partake in calorie 
restriction of 12.5% from baseline and expended an additional 12.5% of baseline energy 
intake (25% total caloric reduction), ASCVD risk is reduced by 39% compared to 29% 
with CalR alone. Although the combination of diet and exercise is ubiquitously 
suggested as a means to reduce ASCVD, the effects of these interventions alone or 
combined and assessed by lipoprotein density distribution remains to be exhaustively 
characterized. 
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Exercise recommendations for reducing ASCVD risk 
Despite the variable response of lipoproteins to exercise, exercise is nonetheless 
associated with reduced ASCVD risk. Multiple organizations issued recommendations to 
increase physical activity to reduce both the risk of developing and for treating ASCVD 
(44, 59, 81, 105, 184). The AHA recommends 150 minutes per week of moderate 
exercise or 75 minutes per week of vigorous exercise (or a combination of moderate and 
vigorous activity) for general cardiovascular health, while those with high blood 
pressure or high cholesterol are encouraged to engage in 40 minutes of moderate 
intensity exercise three or four times weekly (55). Other organizations such as the 
ACSM and NHLBI echo these recommedations (70, 94, 141, 206). These exercise 
duration thresholds are based on combined epidemeological data that summarily show a 
dramatic reduction in ASCVD risk at or near durations of 90 minutes of physical activity 
weekly.  
As outlined above, assessing the efficacy of diet and exercise interventions on 
ASCVD risk relies heavily on the individual’s baseline anthropometrics, degree of 
previous exercise training, a multitude of exercise-related factors and conditions, and 
pre-existing medical conditions that may influence lipoproteins. It seems that current 
lipid panel is best used in the assessment of changes in apoB-containing lipoprotein 
parameters. However, this technique appears inadequate to characterize the functionally 
and physicochemically diverse particles that can be isolated within the nominal HDL 
fraction of plasma. For these reasons assessment techniques that go beyond 
measurement of lipoprotein cholesterol content are necessary to adequately describe risk 
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and/or benefit associated with particles recoverable within the HDL density fraction of 
plasma.    
Statistical methods to assess high dimensional and interdependent data 
Given the high probability of confounding variables in lifestyle modification 
intervention studies, a statistical test to control for these dimensions is desired. Although 
a one-way or two-way analysis of variance (ANOVA) can be conducted, the statistical 
power of such repeated measures is inherently biased due to the increased error rate 
when ANOVA is conducted in series (74). Although a number of post hoc tests could 
theoretically account for this bias, the risk of neglecting the influence of continuous and 
binary variables when assessed in unison on the dependent variables still remains. 
Furthermore, a T-Test cannot distringuish the effects of a binary variable such as gender 
and multiple dependent variables or responses without neglecting to assess the influence 
of the covariates (90). Thus, the use of a multivariate analysis of variance (MANOVA) 
or multivariate analysis of covariance (MANCOVA) is warranted (62).   
Plasma transport of sphingosine 1-phosphate (S1P) 
Upon secretion into plasma, S1P is bound to either albumin (20%) or lipoproteins 
(80%), with HDL being the primarily lipoprotein (>85%) (126, 132, 190, 222). More 
recent studies indicate considerable heterogeniety with the contribution of albumin and 
HDL to S1P transport (83, 109, 132, 189).  Egress of S1P from erythrocytes is critically-
dependent on the presence of albumin or HDL (207). Albumin-bound S1P signaling is 
neither enhanced nor degraded, but HDL-bound S1P (HDL-S1P) exhibits enhanced 
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signaling and can indirectly increase total plasma S1P by increasing transport capacity 
and S1P production (24, 38). 
The transport of S1P on albumin is not fully understood. Modeling has revealed 
that S1P is not bound to albumin but rather co-localized in close proximity to albumin, 
perhaps to increase S1P solubility (4). On the other hand, S1P is bound to HDL by 
apolipoprotein M (apoM). S1P is transported by HDL only if the HDL particle contains 
apoM; increasing apoM expression in mice (fold or % change) increases plasma S1P 
levels by 267% (38). A member of the lipocalin family, apoM displays anti-parallel β-
sheets that form a hydrophobic binding pocket (37). This pocket allows for the transport 
of S1P by HDL. Plasma HDL-C and apoM expression is strongly correlated; apoM-
knockout mice have a 17% to 21% reduction in HDL-C (226). Recently it was shown 
that patients with CAD have decreased HDL-S1P compared to healthy controls, though 
albumin-bound and free S1P is typically increased (191). Loading HDL with S1P from 
healthy control erythrocytes or C17-sphingosine 1-phosphate can increase the amount of 
HDL-S1P in plasma and improve HDL function in HDL dervived from CAD patients 
(190). Not all HDL carries S1P. The most dense HDL3 subfraction carries approximately 
two to three times the quantity of S1P as the less dense HDL2 subfraction. The 
difference in S1P content  appears attributable to increased apoM content of  HDL3 
compared to HDL2 (114).  
HDL functionality attributed to S1P 
As previously mentioned, the function of HDL goes far beyond RCT. In fact, 
evidence suggests that HDL play a pivotal role in immunology and vascular health 
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(158). Furthermore, diseases states such as atherosclerosis regularly exhibit HDL with 
less functional or even dysfunctional phenotypes (178). Many of the advantageous and 
positive attributes associated with HDL can be attributed to S1P (Figure 4).  
Stimulating endothelial cell proliferation and mobility, inhibiting leukocyte 
adhesion and promoting extravasation of oxidized lipoproteins, stimulating prostacyclin 
and NO production, and inhibit matrix metalloproteinases are all processes influenced by 
HDL-S1P (16, 37, 38, 56, 126, 131, 158, 163, 167, 222). 
The effect of diet and exercise on S1P 
No research currently exists on changes in HDL-S1P quantity following a diet 
and/or exercise intervention. Studies have focused on fluctuations in plasma S1P 
quantity and have mixed results. Acute exercise bouts of one session of cycling at 70% 
VO2 max to exhaustion produces increased plasma S1P release by erythrocytes and 
trained individuals had S1P levels 37% higher than untrained subjects (9). Another study  
found that high-intensity exercise to exhaustion significantly increased plasma S1P, but 
resistance training did not (8). In trained ultramarathon runners, plasma S1P drops 
during exercise and remains reduced until 24 hours following rest from exercise (10). 
Interestingly, this effect is also observed in acute myocardial infarction, with sustained 
reductions in plasma S1P following cardio-injury (111).  
Although the effects of exercise on HDL-S1P is not currently known, the effect 
of exercise on atherosclerosis has been attributed to many of the same processes that are 
influenced by S1P, and therefore could plausibly be attributed to increased HDL-S1P 
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Figure 4. Proposed functions of HDL-S1P. Adapted from (167). 
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following chronic exercise (161). An extensive review by Palmefors et al. (161) 
attributes reduced IL-6, decreased VCAM-1, and reduced ICAM-1 as an effect of 
exercise, though the authors do not give specific mechanisms as to why exercise 
produces such an effect. Coincidentally or not, the benefits of exercise can be mimicked 
by S1P in vivo, which may be the reason exercise has such a dramatic effect on 
atherosclerosis reduction. 
Hypothesis 
Exercise produces effects on lipoprotein particle populations that are independent 
of changes in dietary intake. These effects are most likely to manifest within the HDL 
fraction of plasma and be unrelated to changes in particle cholesterol content per se. 
Changes in VO2max can be used as an index of exercise impact and can be statistically 
related to changes in HDL particle properties. 
This study makes an initial assessment of this hypothesis through the use of an 
isopycnic ultracentrifugal separation methodology to determine whether changes in VO2 
max (absolute and relative LBM VO2 max) can be specifically linked to changes in 
density distributions of lipoprotein subclasses.  
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CHAPTER II 
METHODS 
 
Study inclusion criteria  
To evaluate the effect of diet and exercise on lipoprotein density profiles, and to 
reduce bias associated with body composition and VO2 max changes, only studies 
meeting the following inclusion criteria were considered: study duration of a minimum 
of eight weeks, a negative daily energy balance achieved through either supervised 
exercise intervention or controlled diet restriction of approximately 750 kcals per week 
with outcomes assessed of body composition by DEXA, VO2 max measurements 
utilized standardized protocols, and serum samples properly stored and available for 
analysis. Samples for each subject had to include both pre-intervention baselines and 
post-intervention endpoints, in order to ensure that each subject was compared to their 
own data. Two studies met the required criteria and the details of their design and 
execution are published elsewhere for reference (77, 165).  
Subject characteristics 
The final data set comprised 90 individuals aged 20 – 74 years of age. Gender, 
baseline body composition and VO2 max details of the combined study population are 
shown in (Table 4).  
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Descriptive Statistics 
Gender 74.2% male 25.8% female 
Race 97.8% Caucasian 
  Mean Std deviation 
Age (years) 54.06 14.95 
Height (cm) 173.62 8.36 
Weight (kg) 94.54 15.53 
BMI (kg/m2) 31.23 3.81 
DXA (% body fat) 37.51 8.17 
Fat Mass (kg) 33.74 9.53 
Lean Mass (kg) 55.93 10.55 
Relative VO2 max 
(ml/kg/min) 
24.17 7.06 
Relative LBM VO2 max 
(ml/kg LBM/min) 
40.89 11.21 
Absolute VO2 max 
(L/min) 
2.26 0.67 
 
Table 4. Comparison of merged subject characteristics.  
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High performance lipoprotein density profiling 
High performance lipoprotein density profiling (HPLDP) is a novel laboratory 
technique utilizing NBD-ceramide to pre-stain lipoproteins prior to isopycnic separation 
by ultracentrifugation using a metal ion EDTA salt mixture that self-forms a density 
gradient. This allows for sensitive separation of lipoprotein subclasses that can then be  
quantified by documentation of  the fluorescent dye distribution along the density 
gradient (119). 
The staining and separation of lipoproteins was achieved by mixing 6.0 μl of 
subject serum or plasma that were then mixed with 0.18 M NaBiEDTA. Ten microliters 
of NBD-ceramide (Cayman Chemical, Ann Arbor, Michigan) was reconstituted at a 1 
mg to 1 ml ratio using dimethyl sulfide (Sigma-Aldrich Corp, St. Louis, Missouri) was 
added to the mixture within a 11 mm x 34 mm polycarbonate tube (Beckman-Coulter, 
Palo Alto, California) and incubated at four degrees Celsius for 30 minutes. The mixture 
was then centrifuged using a MLA-130 fixed angle rotor (Beckman-Coulter, Palo Alto, 
California) and an Optima MAX-LP Ultracentrifuge (Beckman-Coulter, Palo Alto, 
California) at 120,000 rpm for six hours at four degrees Celsius with the acceleration and 
deceleration set at “five” and the vacuum at a maximum of 20 microns. Once 
centrifugation was completed, tubes were then transferred to a custom-built enclosure 
which housed an Optical Breadboard (Thorlabs Inc, Newton, New Jersey) with a 
custom-built tube holder and Quantifire CCD camera (Optronics, Muskogee, 
Oklahoma). Flotation of 270 µl of high-performance liquid chromatography-grade 
hexane (Sigma-Aldrich Corp, St. Louis, Missouri) aided in the suppression of the 
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meniscus without disturbing the triglyceride-rich lipoprotein layer (119). The room 
lights were turned off and the tube was illuminated using a metal halide Fiber-Lite 
Illuminator (MH100A, Edmund Industrial Optics, Barrington, New Jersey). Two filters 
(Edmund Industrial Optics, Barrington, New Jersey) matching NBD excitation and 
emission wavelengths were placed in front of the light source and CCD camera 
respectively. The filters chosen to match NBD excitation and emission were a blue-
violet band-pass filter (BG-12) with a wavelength centered at 407 nm and a yellow long-
pass filter (OG-515) with a cut-on wavelength of 515 nm.  
Settings for the Picture Frame camera software (Optronics, Muskogee, 
Oklahoma) were at an exposure time of “3 seconds”, gain of 1.000, and a target intensity 
of 30%. Pixel values of the center of the tube (11-pixel wide) were converted into 
fluorescent intensity using Origin 8.0 software (OriginLab, Northampton, 
Massachusetts) and Origin 2015 (OriginLab, Northampton, Massachusetts) and plotted 
as a function of the tube coordinates (Table 4, Figure 4). Pixel values were converted to 
area under the curve (AUC and %AUC) for each lipoprotein subclass using Microsoft 
Excel 2010 (Microsoft, Redmond, Washington). Image processing included data 
adjustment for 16 pixels divided by 16 bits per pixel (BPP) to ensure accuracy of pixel 
data.  
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Table 5. Lipoprotein subclasses and their density ranges using HPLDP. 
 
 
 
 
 
 
 
 
 
 
 
Lipoprotein Subclass Density Range (g/ml) 
TRL <1.019 
LDL-1 1.019-1.023 
LDL-2 1.023-1.029 
LDL-3 1.029-1.039 
LDL-4 1.039-1.050 
LDL-5 1.050-1.063 
HDL-2b 1.063-1.091 
HDL-2a 1.091-1.110 
HDL-3a 1.110-1.133 
HDL-3b 1.133-1.156 
HDL-3c 1.156-1.179 
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Figure 5. Graphical representation of density versus tube coordinates. of y = A1* exp (-
x/t1) + A2 * exp (-x/t2) + y0, where y is the density value, x is the tube coordinate and 
A1, A2, t1, t2 and y0 are constants. Values were y = -872.17113 + 873.17712 * exp (A2 
/ 10843400) + 0.0000389069 * exp (A2 / 80.00782). 
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Data transformation and analysis  
Sample data was analyzed using SPSS (SPSS Statistics for Windows, Version 
24.0, Armonk, NY). Graphs and tables were either generated within SPSS or using 
Microsoft Excel 2010 (Microsoft, Redmond, Washington).  
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CHAPTER III 
RESULTS 
 
Eighty-eight subjects were included in the final data set, with two subjects 
excluded for abnormal data points observed during box plot visualization. Mean age was 
54.4 ± 14.6 years. Mean height was 68.4 ± 3.2 inches. Mean weight was 209.2 ± 33.4 
lbs. Average BMI was 31.3 ± 3.8 kg/m2. Average DEXA was 37.6 ± 8.2 percent body 
fat. Average fat mass was 33.9 ± 9.4 kg. Average lean mass was 56.1 ± 10.4 kg. Average 
absolute VO2 max was 2.3 ± 0.7 liters O2/min. Average relative VO2 max was 24.0 ± 6.9 
ml O2/kg/min. Average relative LBM VO2 max was 40.7 ± 11.1 ml O2/kg LBM/min.  
After 12 weeks of participating in a diet or exercise intervention, subjects lost an 
average of 3.72 kg weight (-3.9%), lost 3.9 kg of body fat (-11.6%), increased lean mass 
0.62 kg (+1.1%), and reduced body fat percentage by 3.41% (-9.1%). Average absolute 
VO2 max increased 0.16 liters O2/min (+7.1%). Average relative VO2 max increased 
2.65 ml O2/kg/min (+11.0%). Average relative LBM VO2 max increased 2.36 ml O2/kg 
LBM/min (+5.8%). A paired-samples T-Test indicated that all metrics were significantly 
changed from baseline (p<0.05). Lipid profiles are summarized in Table 6. Statistically   
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Table 6. Baseline and final lipid profiles of all subjects. AUC = area under the curve 
(arbitrary units), %AUC = percent of area under the curve. * indicates significance 
(p<0.05). 
  
Density 
Fraction 
Baseline Final Change 
mean SD mean SD Gross %Δ 
TRL 452.60 269.78 402.61 325.50 -49.99 5.46 
LDL-1 70.60 37.58 71.65 53.73 1.04 14.31 
LDL-2 108.92 46.74 97.91 49.25 -11.01 -4.20* 
LDL-3 308.87 135.57 306.72 166.12 -2.14 4.43 
LDL-4 718.16 369.22 677.31 384.78 -40.85 -1.38 
LDL-5 471.37 211.91 435.83 248.31 -35.54 -3.63 
LDL Total 1677.93 801.01 1589.42 902.19 -88.51 -3.71 
HDL-2b 546.05 251.30 524.25 283.48 -21.80 0.56 
HDL-2a 516.45 207.57 455.44 201.33 -61.00 -7.23* 
HDL-3a 688.29 170.83 593.30 153.26 -94.99 -10.57* 
HDL-3b 466.29 116.75 414.97 106.98 -51.32 -6.39* 
HDL-3c 178.99 46.94 171.88 53.67 -7.11 0.48 
HDL Total 2396.06 793.39 2159.84 798.72 -236.22 -7.43* 
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Table 6 continued. Baseline and final lipid profiles of all subjects, n = 88. AUC = area 
under the curve (arbitrary units), %AUC = percent of area under the curve. * indicates 
significance (p<0.05). 
 
 
 
 
 
 
 
 
  Density 
Fraction 
Baseline Final Change 
mean SD Mean SD Gross %Δ 
LDL-1 %AUC 1.53 0.66 1.68 0.90 0.15 -- 
LDL-2 %AUC 2.38 0.73 2.33 0.83 -0.06 -- 
LDL-3 %AUC 6.74 2.07 7.19 2.61 0.45 -- 
LDL-4 %AUC 15.49 5.30 15.76 5.67 0.28 -- 
LDL-5 %AUC 10.40 3.71 10.18 3.81 -0.22 -- 
LDL Total 
%AUC 
36.54 12.47 37.13 13.82 0.59 -- 
HDL-2b 
%AUC 
11.99 4.10 12.72 5.03 0.73 -- 
HDL-2a 
%AUC 
11.40 3.36 11.13 3.63 -0.26 -- 
HDL-3a 
%AUC 
15.42 2.64 14.75 2.99 -0.68 -- 
HDL-3b 
%AUC 
10.54 2.39 10.44 2.79 -0.10 -- 
HDL-3c 
%AUC 
4.10 1.19 4.33 1.37 0.22 -- 
HDL Total 
%AUC 
53.45 13.68 53.37 15.80 -0.08 -- 
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significant findings were decreased LDL-2 (-4.20%), HDL-3a (-10.57%), HDL-3b        
(-6.39%), and Total HDL (-7.43%) (p<0.05). 
Differences between diet and exercise interventions 
Using a priori knowledge, subjects separated into diet and exercise groups to 
ascertain if differences existed between interventions (Table 7). No differences existed 
at baseline. Using percent change from baseline, an independent T-Test was used to 
detect differences between interventions at 12 weeks. Significant differences were 
detected between groups (Table 7). Lipoprotein density distributions for diet and 
exercise were -17.14% vs 19.65% for TRL, -26.06% vs 8.14% for LDL5, -19.12% vs -
0.71% for HDL3b, and -17.88% and 7.94% for HDL3c, respectively.  
Characterizing anthropometrics and lipid profiles of subjects who changed VO2 metrics 
Since these findings were unexpected, we explored the effects of 
cardiorespiratory fitness on lipoprotein subfraction density distributions alone by 
dividing subjects into two groups: those who reduced absolute VO2 max and those who 
increased absolute VO2 max. The intent was to determine if differences exist between 
each group’s anthropometric measurement and lipid profile changes that would be 
specifically attributable to exercise. At baseline, there were no significant differences 
between these subjects expect for baseline absolute VO2 max which differed 
approximately 13% between subjects; since percent change was used to baseline and 
final measurements, this variance between groups was accounted for in the 
normalization process and did not impact results.    
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Table 7. Differences between diet and exercise interventions. Data expressed as percent 
change from baseline. *indicates significance (p<0.05). **indicates significance 
(p<0.001) 
 
 
 
 
 
 
%Δ Diet (32) Exercise (56) 
Mean Std. 
Deviation 
Mean Std. 
Deviation 
Weight -9.35** 4.24 -0.78** 2.66 
DXA -17.50** 11.05 -4.64** 6.65 
BMI -9.35** 4.24 -0.83** 2.62 
Lean Mass -0.44* 3.75 1.97* 3.78 
Fat Mass -24.76** 12.62 -4.70** 7.30 
Abs VO2 -4.10** 8.51 12.87** 12.74 
Rel VO2 5.93** 9.52 13.85** 12.87 
Rel LBM VO2 -3.62** 8.31 10.79** 13.20 
Total HDL -12.25 17.96 -6.26 22.15 
Total LDL -15.37* 27.71 2.60* 29.30 
TRL -17.14* 52.02 19.65* 103.51 
LDL1 10.98 58.48 17.74 85.40 
LDL2 -11.43 41.31 0.60 40.71 
LDL3 -5.77 35.34 9.52 54.46 
LDL4 -11.02 32.41 3.78 40.49 
LDL5 -26.06** 25.48 8.14** 41.84 
HDL2b 0.15 27.04 -0.35 39.87 
HDL2a -6.59 23.45 -9.11 34.89 
HDL3a -15.55 18.40 -9.65 24.83 
HDL3b -19.12* 21.24 -0.71* 31.29 
HDL3c -17.88** 21.75 7.94** 31.38 
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Approximately 33% of subjects (n=29) reduced absolute VO2 max while 65% of 
subjects (n=57) improved absolute VO2 max. Twenty-five percent of subjects who 
participated in the diet intervention and 89% of subjects who participated in an exercise 
intervention improved their absolute VO2 max. Characteristics of subjects who improved 
absolute VO2 max and subjects who reduced absolute VO2 max are summarized in 
Table 8 / Figure 6. As expected, subjects in these groups had unequal variance between 
groups as assessed by Levene’s Test for Equality of Variance (p<0.05). Interestingly, the 
variance existed predominately in the subjects’ lipoprotein subfractions distribution in 
LDL and HDL regions and not within Total LDL AUC and Total HDL AUC as might be 
captured by cholesterol measurements. Nevertheless, the violation of homogeneity was  
expected due to heterogeneity observed using arbitrary fluorescent pixel units and, more 
prominently, when unequal group sizes exist. Outliers were visually identified using a 
boxplot, and two outliers were removed from the analysis from both groups. A modified 
T-Test (Welch’s T-Test) was utilized to account for the heterogeneity of variance.  
Significant differences in weight loss (-8.2 % versus -1.4 %), fat mass reduction 
(-21.8 % versus -6.3 %), lean mass accrual (-0.8 % versus +2.2 %), and trunk fat 
reduction (-25.7 % versus +6.3 %) exist between subjects who increased absolute VO2 
max and subjects who reduced absolute VO2 max (p<0.05). Significant differences with 
lipid profiles also were found between subjects who increased absolute VO2 max and 
subjects who reduced absolute VO2 max: TRL AUC (-15.7% versus +17.5%), LDL-5 
AUC (-24.6% versus +7.3%), HDL-3b AUC (-17.3% versus -0.3%) and HDL-3c AUC  
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Table 8. Comparison of positive and negative absolute VO2 max. Overall metrics 
associated with those who increased absolute VO2 max and those who decreased 
absolute VO2 max. All data expressed as percent change from baseline. * indicates 
statistically significant difference between groups at 12 weeks (p<0.05). 
Absolute VO2 Max Change Negative Positive 
Absolute VO2 max -7.6546 14.4188* 
Weight -8.1294 -1.5161* 
DXA -15.3738 -5.8238* 
BMI -8.1275 -1.5622* 
Lean Mass -0.7900 2.0721* 
Fat Mass -21.9624 -6.3274* 
Trunk Fat -25.9532 -7.6616* 
TRL -19.2447 18.9331* 
LDL-1 0.7656 21.9970* 
LDL-2 -6.5481 -2.1253 
LDL-3 0.1413 6.3644 
LDL-4 0.1322 -2.0622 
LDL-5 -24.5051 6.4895* 
Total LDL -10.0976 -0.5152 
HDL-2b 0.5051 -0.1038 
HDL-2a -3.2998 -10.3821 
HDL-3a -12.6616 -11.2316 
HDL-3b -19.3863 -1.7316* 
HDL-3c -20.1349 7.4957* 
Total HDL -11.5110 -6.6766 
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Figure 6. Visualization of metrics associated with positive and negative percent      
change in absolute VO2 max. All data expressed as percent change from baseline. 
 
 
 
 
 
 
 
 
 
 
 
  
-30
-20
-10
0
10
20
30
Metrics associated with different absolute VO2 max 
vectors
Absolute VO2 Max Negative
Absolute VO2 Max Positive
 
 
 
  
58 
(-17.6% and +10.3%).  
To determine whether age or gender of the subjects impacted the results 
attributed to changes in absolute VO2 max, a MANCOVA with age categories 
and gender as covariates was conducted (Table X). The influence of absolute VO2 max 
percent change on TRL AUC, LDL-5 AUC, HDL-3b AUC, and HDL-3c AUC percent 
change remained significant after controlling for age, gender, body fat, and a 
combination of the aforementioned variables. Although the assumption of homogeneity 
of covariance was violated, as assessed by a Box’s M test (p<0.001), the robust nature of 
F statistic and using allowed the analysis to continue. Additionally, to account for the 
lack of homoscedasticity Pillai’s Trace was used rather than Wilk’s λ, primarily due to 
its ability to account for unequal variance (62). The results of this test demonstrated that 
absolute VO2 max percent change maintains a significant influence on LDL-5 AUC 
percent change and HDL-3c AUC percent change when controlling for the effects of age 
and gender (p<0.001). Gender did influence HDL-3b AUC percent change significantly, 
F(4, 80) = 1.221, p<0.05, Pillai’s Trace = 0.194, ƞ2 = 0.194. 
A follow-up univariate analysis of variance (ANOVA) was conducted to 
determine the influence of age on LDL-5 AUC percent change, HDL-3c AUC percent 
change, and absolute VO2 max measurements and care was taken to identify differences 
between groups utilizing Bonferroni post hoc analysis and Bonferroni adjustment, the 
latter which can be being described α / m, where m = the number of ANOVA tests 
conducted. Although significance with age was found in the MANCOVA, multiple 
ANOVA and post hoc analysis determined a difference existed only between age 
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categories and relative LBM VO2 max, not lipid profiles. The difference in age 
categories was found between age group 20-29 and age group 60-69 (p<0.017).    
 Significant correlations 
In order to standardize units, all variables were correlated using their percent 
change values which were calculated as (final measurement – baseline measurement) / 
baseline measurement x 100. Over 125 variables were significantly correlated with each 
other as assessed by Pearson Correlation. Most noteworthy, significant positive 
correlations were found between weight and total LDL, weight and total HDL, weight 
and LDL-5, and weight and small HDL (p<0.05). Percent change of body fat was 
positively correlated to the same variables as percent weight change, though the HDL 
fraction of HDL-3a was not. Absolute VO2 max percent change was positively 
correlated with total LDL AUC, LDL-5 AUC, and HDL-3c AUC. Fat mass percent 
change was significantly correlated with TRL percent change, LDL percent change, 
HDL-3b percent change, and HDL-3c percent change.  
A partial correlation was also conducted to determine if fat mass percent change 
explained the changes observed with VO2 max (Table 9). The partial correlation 
indicated that when fat mass percent change was controlled, significant correlations 
continued to exist between absolute VO2 max and LDL5, and absolute VO2 max and 
HDL3c.  
Linear regression    
Linear regression using the aforementioned significant correlations was utilized 
in an effort to construct a prediction equation that would predict a lipoprotein  
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Table 9. Partial correlation analysis controlling for fat mass change.  
 
 
 
 
 
 
 
 
 
Control 
Variables 
 abs VO2 max 
Fat mass 
Rel LBM VO2 
max 
Correlation 0.927 
Significance (2-tailed) 0.000** 
TRL 
Correlation 0.079 
Significance (2-tailed) 0.468 
LDL5 
Correlation 0.239 
Significance (2-tailed) 0.026* 
HDL3b 
Correlation 0.069 
Significance (2-tailed) 0.526 
HDL3c 
Correlation 0.240 
Significance (2-tailed) 0.025* 
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subfraction profile percent change in response to an absolute VO2 max percent change 
(when baseline is known). Various iterations of the equation were attempted to include 
body fat percent change, weight percent change, and covariates such as age categories 
and gender but the universally significant variable to consistently predict changes to the 
HDL-3c AUC was absolute VO2 max percent change. A simple linear regression was 
constructed to identify how HDL-3c AUC percent change is predicted when absolute 
VO2 max percent change is known. A significant regression equation was found using 
an R2 of 0.108, F(1, 87) = 10.537, p<0.002 . Predicting HDL-3c AUC percent change is 
-5.244 + 0.838 (absolute VO2 max percent change) when absolute VO2 max is measured 
as a percent change from baseline. Participants HDL-3c percent change increased 0.838 
for every percent change in absolute VO2 max. 
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CHAPTER IV 
SUMMARY OF FINDINGS AND FUTURE DIRECTION 
 
The phrase “diet and exercise” is used to describe the most common lifestyle 
interventions to reduce ASCVD risk, the research presented here shows that changes in 
select lipoprotein subclass occurred in response to changes in VO2 max regardless of the 
means used to achieve that change. This research also shows the disparity that may exist 
between classic cholesterol panels and subfraction measurements.  
The anthropometric data demonstrates the similar responses to body weight, 
body fat, and BMI scores that result from consistent lifestyle intervention. The 
cardiorespiratory markers however trended differently despite similar anthropometric 
modulations. It appears that changes in HDL-3c are closely if not directly related to 
changes in absolute VO2 max. Research indicates that small dense HDL particles are 
associated with an increased risk for ASCVD (13, 186, 227). For example, Salonen et al. 
(186) reported an inverse correlation between large HDL-C and acute myocardial 
infarction using preparative ultracentrifugation and tube slicing. Xu et al. (227) 
compared HDL-C levels in subjects with and without ASCVD, then subdivided HDL-C 
into subfractions by gel electrophoresis; they reported positive correlations between 
ASCVD and small HDL-C particles.  
There are several plausible reasons why our research appears at odds with these 
findings. Our subjects engaged in a lifestyle intervention, which the clinical endpoints 
used in the aforementioned studies did not assess. We did not clinically-diagnose the 
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presence of ASCVD in our subjects while the majority of studies reporting a relationship 
between small HDL particles and ASCVD risk did assess. Finally, we utilized 
lipoprotein subfractions density distributions rather than lipoprotein cholesterol profiles. 
Our methodology is more specific to density fractional modifications and thus may not 
be replicable using different methodologies.   
Other studies have indicated that exercise does support improved antioxidant 
capacity in HDL-3 subfractions, but to date none have assessed or speculated S1P 
content as the mechanism. High-density lipoproteins have an increase in PON1 activity 
following an exercise intervention in subjects with metabolic syndrome (29). Casella-
Filho et al. (29) found that although HDL-C did not improve with exercise in subjects 
with MetS, PON1 activity increased in the smallest HDL subfraction. Ribeiro et al. (174) 
found that no changes occurred in HDL-C following 18 weeks of exercise in subjects 
with type 2 diabetes, but HDL-3 improved antioxidant capacity as assessed via oxLDL 
generation.  
It is highly plausible that HDL-S1P content is responsible for the improved 
function of HDL-3 subfractions through increased generation of NO and other benefits 
of HDL modulation following exercise, but current methodologies do not assess this 
(208). Our subjects did not significantly change HDL-2b and thus a HDL-C panel would 
not be able to indicate the changes we were able to assess via lipoprotein density 
distributions. As previously mention, S1P is most prominently carried on the HDL-3c 
subfraction (83, 84, 121). Our study found a significant linear relationship between 
improved absolute VO2 max and increased HDL-3c subfraction AUC and indicates that 
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the subfraction may be a strong prognostic indicator of exercise efficacy in relation to 
cardiorespiratory fitness. 
This study utilized a promising technology that can rapidly assess biological 
adaptations to lifestyle interventions and reveal the inefficacious nature of HDL-C if 
measuring effects of lifestyle interventions outside of lipoprotein cholesterol for ASCVD 
risk reduction. This methodology allowed the measurement of specific lipoprotein 
density gradients which revealed far more predictive power that may have been 
overlooked. Finally, this method detected modification to lipoprotein density 
distributions that would have remained obscure if using traditional lipoprotein 
cholesterol assessment methods, especially given the covariates and cofactors of weight, 
body fat, age, and gender.  
Most importantly, this study demonstrates the ubiquitous and complex 
characteristics of lipoprotein subfractions. It highlights the importance of standardizing 
assessment methodologies and characterizing lipoprotein profiles for a specific 
population rather than overgeneralizing findings. The transcending reductionism in diet 
and exercise research may further complicates rather than clarify the complex 
biochemical and physiological adaptations observed following lifestyle intervention. 
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APPENDIX A: NOMENCLATURE 
 
AHA American Heart Association 
apoA1 apolipoprotein A1 
apoA2  apolipoprotein A2 
apoB100 apolipoprotein B100 
apoB48 apolipoprotein B48 
apoCII apolipoprotein CII 
apoCIII apolipoprotein CIII 
apoE apolipoprotein E 
apoM apolipoprotein M 
ASCVD atherosclerotic cardiovascular disease 
CE cholesterol esters 
CETP cholesterol:ester transfer protein 
Chol cholesterol 
CR chylomicron remnant 
CVD cardiovascular disease 
FABP fatty acid binding protein 
FAT/CD36 fatty acid translocase/cluster of determination 36 
HDL high-density lipoprotein 
HDL-C high-density lipoprotein cholesterol 
HDL-S1P high-density lipoprotein-associated sphingosine 1-phosphate 
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HDL-x high-density lipoprotein, subclass/subfraction x 
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A 
HPLDP high performance lipoprotein density profiling 
HSGP heparin sulfate proteoglycan 
ICAM-1 intracellular adhesion molecule-1 
IDL intermediate-density lipoprotein 
LBM lean body mass or non-fat mass 
LDL low-density lipoprotein 
LDL-C low-density lipoprotein cholesterol 
LDL-x low-density lipoprotein, subclass/subfraction x 
LRP lipoprotein remnant receptor protein 
MetS metabolic syndrome 
MRFIT Multiple Risk Factor Intervention Trial 
NHLBI National Heart, Lung, and Blood Institute 
NO nitric oxide 
NMR nuclear magnetic resonance 
oxLDL oxidized low-density lipoprotein 
PCSK9 proprotein convertase subtilisin/kexin 9 
PL phospholipids 
PLTP phospholipid transfer protein 
S1P sphingosine 1-phosphate 
sdLDL small dense low-density lipoproteins 
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SMC smooth muscle cells 
SR-B1 scavenger receptor, type B, class 1 
TAG triacylglycerides 
TC total cholesterol 
VCAM-1  vascular cell adhesion protein-1  
VLDL very-low-density lipoprotein 
VEGF vascular endothelial growth factor 
V̇O2 max volume of oxygen in liters consumed per minute 
 
 
 
 
 
 
 
 
 
 
